Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03337490 · ClinicalTrials.gov registry record · Phase 3
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Phase 3 study, sponsored by Mayne Pharma International Pty.
- Completed
- Registry status
- Phase 3
- Development phase
- 296
- Enrollment target
NCT03337490 is a Phase 3 study that has completed, run by Mayne Pharma International Pty. The registered enrollment target is 296 participants.
The verdict
NCT03337490, a Phase 3 study, has completed, sponsored by Mayne Pharma International Pty.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 296 participants
- Enrollment target
Study Summary
This is a phase 3 randomized, multi-center, double-blind, placebo controlled, parallel group design study.
Interventions
- DRUG Ivermectin 0.5% Topical Application Lotion
- DRUG Ivermectin 0.5% Topical Application Lotion [SKLICE]
- DRUG Placebo 0% Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2017-10-02 |
| Est. Completion | 2017-12-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03337490
The ClinicalTrials.gov registry entry for NCT03337490 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayne Pharma International Pty, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ivermectin 0.5% Topical Application Lotion is the first listed.
NCT03337490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03337490 about?
NCT03337490 is a clinical study titled "A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice". This is a phase 3 randomized, multi-center, double-blind, placebo controlled, parallel group design study.
What is the current status of trial NCT03337490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 296 participants. The study started on 2017-10-02. Estimated completion is 2017-12-18.
What interventions are being tested in trial NCT03337490?
The interventions under investigation include: Ivermectin 0.5% Topical Application Lotion (DRUG), Ivermectin 0.5% Topical Application Lotion [SKLICE] (DRUG), Placebo 0% Lotion (DRUG).
Who is sponsoring clinical trial NCT03337490?
This trial is sponsored by Mayne Pharma International Pty, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.